Dr. Daniel Mark, MD

NPI: 1881778769
Total Payments
$33,340
2024 Payments
$9,071
Companies
7
Transactions
15
Medicare Patients
423
Medicare Billing
$113,602

Payment Breakdown by Category

Consulting$32,144 (96.4%)
Travel$622.65 (1.9%)
Food & Beverage$573.02 (1.7%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $32,144 7 96.4%
Travel and Lodging $622.65 2 1.9%
Food and Beverage $573.02 6 1.7%

Top Paying Companies

Company Total Records Latest Year
Boehringer Ingelheim Pharmaceuticals, Inc. $9,071 1 $0 (2024)
NOVARTIS PHARMACEUTICALS CORPORATION $7,023 3 $0 (2023)
Boehringer Ingelheim International GmbH $6,300 1 $0 (2023)
Novo Nordisk Inc $6,000 1 $0 (2018)
Janssen Global Services, LLC $4,652 4 $0 (2017)
Medtronic Vascular, Inc. $184.14 2 $0 (2020)
Merck Sharp & Dohme Corporation $110.00 3 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $9,071 1 Boehringer Ingelheim Pharmaceuticals, Inc. ($9,071)
2023 $8,700 2 Boehringer Ingelheim International GmbH ($6,300)
2022 $3,000 1 Novartis Pharmaceuticals Corporation ($3,000)
2021 $1,623 1 NOVARTIS PHARMACEUTICALS CORPORATION ($1,623)
2020 $96.39 1 Medtronic Vascular, Inc. ($96.39)
2019 $110.00 3 Merck Sharp & Dohme Corporation ($110.00)
2018 $6,000 1 Novo Nordisk Inc ($6,000)
2017 $4,739 5 Janssen Global Services, LLC ($4,652)

All Payment Transactions

15 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
09/23/2024 Boehringer Ingelheim Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $9,071.25 General
11/16/2023 Boehringer Ingelheim International GmbH Consulting Fee Cash or cash equivalent $6,300.00 General
01/19/2023 NOVARTIS PHARMACEUTICALS CORPORATION LEQVIO (Drug) Consulting Fee Cash or cash equivalent $2,400.00 General
Category: Cardiology/Vascular Diseases
01/17/2022 Novartis Pharmaceuticals Corporation LEQVIO (Drug) Consulting Fee Cash or cash equivalent $3,000.00 General
Category: CARDIOVASCULAR
11/05/2021 NOVARTIS PHARMACEUTICALS CORPORATION LEQVIO (Drug) Consulting Fee Cash or cash equivalent $1,623.00 General
Category: CARDIOVASCULAR
02/08/2020 Medtronic Vascular, Inc. Reveal LINQ (Device) Food and Beverage In-kind items and services $96.39 General
Category: Cardiac Diagnostics and Monitoring
03/19/2019 Merck Sharp & Dohme Corporation MK-1242 (Drug) Food and Beverage In-kind items and services $50.00 General
Category: CARDIOVASCULAR
03/19/2019 Merck Sharp & Dohme Corporation MK-1242 (Drug) Food and Beverage In-kind items and services $35.00 General
Category: CARDIOVASCULAR
03/19/2019 Merck Sharp & Dohme Corporation MK-1242 (Drug) Food and Beverage In-kind items and services $25.00 General
Category: CARDIOVASCULAR
09/10/2018 Novo Nordisk Inc Consulting Fee Cash or cash equivalent $6,000.00 General
08/16/2017 Janssen Global Services, LLC Consulting Fee Cash or cash equivalent $3,750.00 General
08/16/2017 Janssen Global Services, LLC Travel and Lodging In-kind items and services $594.65 General
08/16/2017 Janssen Global Services, LLC Food and Beverage In-kind items and services $278.88 General
08/16/2017 Janssen Global Services, LLC Travel and Lodging Cash or cash equivalent $28.00 General
02/07/2017 Medtronic Vascular, Inc. Reveal LINQ (Device) Food and Beverage In-kind items and services $87.75 General
Category: Cardiac Diagnostics and Monitoring

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 2 97 187 $123,988 $25,326
2022 2 97 189 $136,748 $28,723
2021 2 64 154 $112,060 $23,501
2020 2 165 305 $148,584 $36,052
Total Patients
423
Total Services
835
Medicare Billing
$113,602
Procedure Codes
8

All Medicare Procedures & Services

8 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99291 Critical care, first 30-74 minutes Facility 2023 65 126 $108,738 $20,487 18.8%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 32 61 $15,250 $4,839 31.7%
99291 Critical care, first 30-74 minutes Facility 2022 69 146 $125,998 $25,349 20.1%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 28 43 $10,750 $3,374 31.4%
99291 Critical care delivery critically ill or injured patient, first 30-74 minutes Facility 2021 48 120 $103,560 $20,752 20.0%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 16 34 $8,500 $2,749 32.3%
99291 Critical care delivery critically ill or injured patient, first 30-74 minutes Facility 2020 80 118 $101,834 $20,765 20.4%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 85 187 $46,750 $15,286 32.7%

About Dr. Daniel Mark, MD

Dr. Daniel Mark, MD is a Cardiovascular Disease healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881778769.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Mark, MD has received a total of $33,340 in payments from pharmaceutical and medical device companies, with $9,071 received in 2024. These payments were reported across 15 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($32,144).

As a Medicare-enrolled provider, Mark has provided services to 423 Medicare beneficiaries, totaling 835 services with total Medicare billing of $113,602. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.

Practice Information

  • Specialty Cardiovascular Disease
  • Location Durham, NC
  • Active Since 10/25/2006
  • Last Updated 10/04/2007
  • Taxonomy Code 207RC0000X
  • Entity Type Individual
  • NPI Number 1881778769

Products in Payments

  • LEQVIO (Drug) $7,023
  • Reveal LINQ (Device) $184.14
  • MK-1242 (Drug) $110.00

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Cardiovascular Disease Doctors in Durham